Core Viewpoint - The announcement highlights the approval of a new specification for the drug Treprostinil Injection by the National Medical Products Administration, indicating a significant development for the company and its product line in the treatment of pulmonary arterial hypertension (PAH) [1] Group 1: Product Approval - The new specification of Treprostinil Injection (20ml:50mg) received its drug registration certificate on September 22 [1] - The existing specification (20ml:20mg) was approved for market launch in March 2023 [1] Group 2: Market Position - Treprostinil Injection is listed in the medical insurance catalog and serves as a first-line treatment for PAH [1] - It is the only drug in China that can be administered subcutaneously and intravenously for the treatment of PAH, positioning the company uniquely in the market [1]
远大医药：曲前列尼尔注射液新规格国内获批